Your browser do not use CSS. Please, ignore the following images.

HOME PRODUCTS CORONARY TITAN2 (BAS)

Coronary
Bio Active Stent (BAS)
pre-mounted on
rapid exchange PTCA
polyamide catheter

TITAN2 BAS (Bio Active Stent) is the unique alternative to DES (Drug Eluting Stent) offering superior deliverability, proven clinical efficacy and long term safety.

TITAN2 is based on the unique Helistent helicoïdal design which has demonstrated its exceptional behaviour in terms of clinical results through various studies enrolling more than 5000 patients.

Coating Technology

More than 3 years of R&D have been necessary for Hexacath to develop the Titanium-NO Bio Active Coating using the latest developments in Metal and Gaz Nanosynthesis technology.

The Hexacath proprietary process allows to combine the benefits of both pure Titanium as well as NO-particles present on the stent surface.

TITAN2 Superiority

The TITAN2 Bio Active Stent is combining the benefits of its Titanox coating (Titanium-Nitride-Oxide) with the exclusive biomechanical features (ultra low profile and excellent flexibility) of its Helicoidal designed stent platform thus enabling the interventional cardiologist to perform a PTCA procedure in a reduced time.

The mechanism of action of this active coating includes the inhibition of platelet aggregation and fibrinogen binding combined with a minimized inflammatory response due to the complete prevention of toxic ions release reducing consequently the restenosis rate and the clinical events at follow up.

Titanium-Nitride-Oxide superior hemo compatibility further reduces acute or sub-acute thrombosis versus conventional stents made in stainless steel or cobalt-chromium, and on the opposite of Drug-Eluting-Stent, does not impede the stent re-endothelization process thus eliminating the risk of very late stent thrombosis.

The stent re-endothelization is fundamental and critical for the patient safety. Drug-Eluting-Stents tend to prevent the normal cells' growth inside the stent (re-endothelization) necessary to avoid thrombosis and therefore require long term dual antiplatelet treatments from 12 months up to a lifetime.

On the contrary, patients treated with TITAN2 do not need a long term dual antiplatelet treatment (1 month only) reducing therefore the risk of bleeding.

TITAN2 impressive series of clinical results show that a Biologically Active Coating (Titanium-Nitride-Oxide) can be as effective as a Drug-Eluting-Stent (DES) in terms of clinical restenosis with much less risk of late or very late stent thrombosis.

Technical specifications

Usable length: 140cm
Shaft diameter:
- Polytube 2.6F (0.84mm)
- Hypotube 1.7F (0.58mm)
Minimum guiding catheter diameter:
- 5F (0.058") for 2.0 to 4.0mm
- 6F (0.064") for 4.5 to 5.0mm
Maximum guide wire diameter: 0.014" (0.356mm)
Radio-opaques markers:
One at each end of stent
Material composition:
316L stainless steel
Coating: Titanium-NO

EFFICACY

Randomized populations

3 independent randomized studies vs BMS have proven TITAN2 BAS can reduce Late Loss by 39%, Restenosis by 71%, TLR by 76% and MACE by 88%.

Unselected populations

An independent comparative and prospective registry enrolling 400 patients has shown that TITAN2 BAS is as effective as PES (Paclitaxel Eluting Stents) in reducing TLR and MACE at 12 monts but SAFER IN TERMS OF AMI.

High risk populations

The TITAN2 BAS, like DES, has shown efficacy and excellent clinical results in the most CHALLENGING PATIENTS such as DIABETICS or in the most complex indications such as SMALL VESSELS..

SAFETY

Lowest acute and sub acute levels of thrombosis
with no late or very late thrombosis

The TITAN2 BAS doesn't impede THE NATURAL PROCESS OF RE-ENDOTHELIALIZATION and doesn't induce NEGATIVE LATE LOSS, two potential causes of THROMBOSIS. On the contrary, by promoting re-endothelialization, the TITAN2 BAS ACCELERATES the healing process post-stenting.

Absence of Polymer

The TITAN2 BAS superior BIOCOMPATIBILITY outperforms any type of coating including bioabsorbable polymers, and therefore REDUCES inflammatory and hypersensitivity reactions linked with thrombosis.

Long term dual antiplatelet treatment not required

The TITAN2 BAS is avoiding BOTH the BLEEDING risks and the risks of THROMBOSIS (29%) associated with long term dual antiplatelet treatment or its discontinuation..

Unmatched safety

A series of clinical studies enrolling more than 5000 patients have fully demonstrated the TITAN2 BAS safety.

DURABILITY

Advantage over time

The TITAN2 BAS has not been associated with any LATE CATCH UP, a phenomenon largely observed with DES after 3 or 4 years and anticipated in the animal model by Virmani et al.

Unique confidence level

TITAN2 BAS 5 years of sustained Efficacy and Safety in more than 20 countries set unprecedented standard in the industry.

DELIVERABILITY

Exceptional flexibility

VARIABLE STRUT technology with stent strut thickness adapted to the vessel diameter (minimum: 70 microns/0.0027")

Outstanding navigability

HYDROPHYLIC COATING on balloon carrier distal shaft AND tip
Proximal and distal shafts with lowered profiles
Mini shoulder concept

Superior crossability

ULTRA LOW stent profile (0.8mm/0.031" to 1mm/0.039") according to diameter
Wedge strut proprietary process

Excellent angiographic results

HELICOIDAL DESIGN giving enhanced conformability allowing to treat bifurcations and providing good Side Branch Access

Coronary Bio Active Stent (BAS) pre-mounted on rapid exchange PTCA polyamide catheter